Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pernix To Acquire Somaxon | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pernix To Acquire Somaxon

Gains insomnia drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pernix Therapeutics has entered into a definitive merger agreement to acquire Somaxon in a stock-for-stock transaction valued at $25 million. Pernix gains Somaxon’s Silenor (doxepin) for the treatment of insomnia, which had YTD sales of approximately $11.7 million.
 
Cooper Collins, president and chief executive officer of Pernix, said, “The acquisition of Somaxon is another important step in the growth strategy of Pernix, which is expected to continue to expand our product portfolio, in addition to our recently announced agreements to acquire Cypress Pharmaceuticals and Hawthorn Pharmaceuticals. Somaxon’s product Silenor, which is a non-seasonal product, broadens our branded product line and may also have potential as an OTC product in the future.”
 
Richard W. Pascoe, Somaxon’s president and chief executive officer, said, “We believe this acquisition will provide the opportunity to more fully capitalize on the Silenor brand. Moreover, with Pernix’s recently announced acquisition of Cypress and Hawthorn, we believe that the combined entity, with its broad platform of branded, generic and OTC products, represents long-term value for the benefit of all of our stockholders. We look forward to working with the Pernix management team as we integrate Somaxon with Pernix.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters